Cargando…

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study

PURPOSE: The aim of the study was to delineate the disease characteristics, the initial treatment patterns, and survival in patients with mantle cell lymphoma (MCL) managed in the real world. METHODS: Data of 518 MCL patients from 5 major Chinese Hematology Centers in the period from 2007 to 2017 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Meng, Li, Yun, Huang, Huiqiang, Xu, Wei, Wang, Yanyan, Huang, Haiwen, Zhao, Weili, Liu, Shuo, Xu, Pengpeng, Chen, Zhengming, Zhu, Jun, Song, Yuqin, Ruan, Jia, Wu, Depei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763847/ https://www.ncbi.nlm.nih.gov/pubmed/35059312 http://dx.doi.org/10.3389/fonc.2021.770988

Ejemplares similares

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
por: Wang, Shuo, et al.
Publicado: (2021)

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
por: Yamshon, Samuel, et al.
Publicado: (2023)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma
por: Holik, Hrvoje, et al.
Publicado: (2015)

G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Mantle Cell Lymphoma Growth in Preclinical Models
por: Zhou, Lixia, et al.
Publicado: (2021)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022)

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2023)

Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report
por: Adashek, Michael, et al.
Publicado: (2018)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
por: Marcacci, Gianpaolo, et al.
Publicado: (2021)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2021)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era
por: Mussetti, Alberto, et al.
Publicado: (2015)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
por: Martin, Peter, et al.
Publicado: (2023)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Sarcoid-Like Reaction in the Kidney Following Rituximab for Mantle Lymphoma in a 60-Year-Old Man
por: Mrabet, Sanda, et al.
Publicado: (2023)

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma
por: Zhong, Huijuan, et al.
Publicado: (2019)

P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
por: Shotton, Rohan, et al.
Publicado: (2023)

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
por: Inamdar, Arati A., et al.
Publicado: (2016)

Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead
por: Sun, Ming, et al.
Publicado: (2019)

Spontaneous Splenic Rupture and Rituximab-Induced Acute Thrombocytopenia in a Patient with High-Risk Mantle Cell Lymphoma
por: Williams, Jared, et al.
Publicado: (2019)

Epstein–Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non–Hodgkin lymphoma: the prevalence and impacts on outcomes: EBV and CMV reactivation post allo-HCT in NHL
por: Ding, Yiyang, et al.
Publicado: (2021)

Tracheobronchial involvement of mantle cell lymphoma
por: Tong, Lin, et al.
Publicado: (2018)

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
por: Nakamura, Nobuhiko, et al.
Publicado: (2022)

Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma
por: Narkhede, Mayur, et al.
Publicado: (2022)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Improvement of the rituximab–induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines
por: Doignon, Isabelle, et al.
Publicado: (2019)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_38ipd3mtslu2jhc5tocihaef3q